Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
65.9M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
16.3M
-
Shares change
-
-76.2K
-
Total reported value, excl. options
-
$15.3M
-
Value change
-
-$76.2K
-
Number of buys
-
21
-
Number of sells
-
-12
-
Price
-
$0.93
Significant Holders of Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) as of Q3 2025
51 filings reported holding CTSO - Cytosorbents Corp - Common Stock, par value $0.001 per share as of Q3 2025.
Cytosorbents Corp - Common Stock, par value $0.001 per share (CTSO) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.3M shares
of 65.9M outstanding shares and own 24.79% of the company stock.
Largest 10 shareholders include AVENIR CORP (5.08M shares), VANGUARD GROUP INC (2.2M shares), Skylands Capital, LLC (2.13M shares), NEUBERGER BERMAN GROUP LLC (1.6M shares), CM Management, LLC (1.29M shares), BlackRock, Inc. (765K shares), Sargent Investment Group, LLC (739K shares), GEODE CAPITAL MANAGEMENT, LLC (601K shares), CIBC Private Wealth Group LLC (173K shares), and STATE STREET CORP (159K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.